

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment ID6425

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Roche (inavolisib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Breast Cancer Now	Wales
Breast Cancer UK	British National Formulary
Cancer Black Care	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health - Northern Ireland
 Independent Cancer Patients Voice 	Healthcare Improvement Scotland
Inflammatory Breast Cancer (IBC)	Medicines and Healthcare products
Network UK	Regulatory Agency
Lobular Breast Cancer UK	National Association of Primary Care
Macmillan Cancer Support	National Pharmacy Association
Maggie's Centres	NHS Confederation
	Scottish Medicines Consortium
	Welsh Government
METUDIU	
	Welsh Health Specialised Services Committee
Prevent Breast Cancer South Asian Health Foundation	Committee
South Asian Health Foundation	Possible comparator companies
Specialised Healthcare Alliance	AstraZeneca (capivasertib, fulvestrant)
Tenovus Cancer Care	Dr. Reddy's Laboratories (everolimus,
Llockhoore professional groups	fulvestrant)
Healthcare professional groups	Eli Lilly (abemaciclib, imlunestrant)
Association of Breast Surgery Association of Conser Physicians	Ethypharm UK Ltd (everolimus)
Association of Cancer Physicians Dittale Cariatria Cariatri	Genus Pharmaceuticals (fulvestrant)
British Geriatrics Society	• • • • • • • • • • • • • • • • • • •
British Institute of Radiology British Organisms Pharmaners	
British Oncology Pharmacy Association	(exemestane)
Association	Medical Valley Invest AB (fulvestrant)Menarini Stemline (elacestrant)
British Psychosocial Oncology Society	,
British Society of Interventional Bartisla and Table 1999 British Society of Interventional British Society of Interventional British Society of Interventional	Mylan (exemestane)
Radiology	Novartis (alpelisib, everolimus, with a siglib.)
Cancer Research UK	ribociclib)

Provisional stakeholder list for the evaluation of inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment ID6425



Provisional Consultees Provisional Commentators (no right to submit or appeal) Royal College of General Practitioners Pfizer (exemestane, palbociclib) Royal College of Nursing Ranbaxy (fulvestrant) Royal College of Pathologists Rivopharm (exemestane) Royal College of Physicians Sandoz (everolimus, fulvestrant) Royal College of Radiologists • Sun Pharmaceutical Industries Europe Royal Pharmaceutical Society B.V. (fulvestrant) Royal Society of Medicine Teva UK (everolimus, fulvestrant) Zentiva (exemestane, fulvestrant) Society and College of Radiographers **UK Breast Cancer Group** Relevant research groups **UK Clinical Pharmacy Association Against Breast Cancer UK Oncology Nursing Society** Breast Cancer Hope Cochrane Breast Cancer Group Others · Genomics England Department of Health and Social Care Institute of Cancer Research NHS England MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund Associated Public Health groups **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment ID6425



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.